Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer

Dannah R. Miller, Cherng Chyi Tzeng, Trey Farmer, Evan T. Keller, Steven H Caplan, Yu Shuin Chen, Yeh Long Chen, Ming-Fong Lin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The standard-of-care treatment for metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). Nevertheless, most tumors eventually relapse and develop into lethal castration-resistant prostate cancer (CRPC). Docetaxel is a FDA-approved agent for the treatment of CRPC; however, the tumor often quickly develops resistance to this drug. Thus, there is an immediate need for novel therapies to treat docetaxel-resistant PCa. In this study, we modified the structure of CIL-102 and investigated the efficacy of the derivatives against CRPC and docetaxel-resistant PCa. These novel CIL-102 derivatives inhibit CRPC tumorigenicity, including proliferation, migration and colony formation, and importantly, selectively inhibit CRPC cell proliferation over non-cancerous prostate epithelia. Computational modeling indicated the derivatives bind to β-tubulin and immunocytochemistry revealed the depolymerization of microtubules upon treatment. Western blot analyses reveal that pro-apoptotic and anti-oxidant pathways are activated, and MitoSOX and DCF-DA analyses confirmed increased reactive oxygen species (ROS) production upon treatments. Furthermore, CIL-102 derivatives effectively reduce the proliferation of docetaxel-resistant CR PCa cell lines. Our data indicate the potential of these compounds as promising therapeutic agents for CRPC as well as docetaxel-resistant CRPC.

Original languageEnglish (US)
Pages (from-to)96-108
Number of pages13
JournalCancer Letters
Volume436
DOIs
StatePublished - Nov 1 2018

Fingerprint

docetaxel
Prostatic Neoplasms
Castration
Therapeutics
1-(4-(furo(2,3-b)quinolin-4-ylamino)phenyl)ethanone

Keywords

  • Anti-microtubule agents
  • CIL-102 derivatives
  • CR PCa
  • Docetaxel-resistant cancer
  • Selectivity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. / Miller, Dannah R.; Tzeng, Cherng Chyi; Farmer, Trey; Keller, Evan T.; Caplan, Steven H; Chen, Yu Shuin; Chen, Yeh Long; Lin, Ming-Fong.

In: Cancer Letters, Vol. 436, 01.11.2018, p. 96-108.

Research output: Contribution to journalArticle

Miller, Dannah R. ; Tzeng, Cherng Chyi ; Farmer, Trey ; Keller, Evan T. ; Caplan, Steven H ; Chen, Yu Shuin ; Chen, Yeh Long ; Lin, Ming-Fong. / Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. In: Cancer Letters. 2018 ; Vol. 436. pp. 96-108.
@article{97b421707605439c878fcf7345358524,
title = "Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer",
abstract = "The standard-of-care treatment for metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). Nevertheless, most tumors eventually relapse and develop into lethal castration-resistant prostate cancer (CRPC). Docetaxel is a FDA-approved agent for the treatment of CRPC; however, the tumor often quickly develops resistance to this drug. Thus, there is an immediate need for novel therapies to treat docetaxel-resistant PCa. In this study, we modified the structure of CIL-102 and investigated the efficacy of the derivatives against CRPC and docetaxel-resistant PCa. These novel CIL-102 derivatives inhibit CRPC tumorigenicity, including proliferation, migration and colony formation, and importantly, selectively inhibit CRPC cell proliferation over non-cancerous prostate epithelia. Computational modeling indicated the derivatives bind to β-tubulin and immunocytochemistry revealed the depolymerization of microtubules upon treatment. Western blot analyses reveal that pro-apoptotic and anti-oxidant pathways are activated, and MitoSOX and DCF-DA analyses confirmed increased reactive oxygen species (ROS) production upon treatments. Furthermore, CIL-102 derivatives effectively reduce the proliferation of docetaxel-resistant CR PCa cell lines. Our data indicate the potential of these compounds as promising therapeutic agents for CRPC as well as docetaxel-resistant CRPC.",
keywords = "Anti-microtubule agents, CIL-102 derivatives, CR PCa, Docetaxel-resistant cancer, Selectivity",
author = "Miller, {Dannah R.} and Tzeng, {Cherng Chyi} and Trey Farmer and Keller, {Evan T.} and Caplan, {Steven H} and Chen, {Yu Shuin} and Chen, {Yeh Long} and Ming-Fong Lin",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.canlet.2018.07.039",
language = "English (US)",
volume = "436",
pages = "96--108",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer

AU - Miller, Dannah R.

AU - Tzeng, Cherng Chyi

AU - Farmer, Trey

AU - Keller, Evan T.

AU - Caplan, Steven H

AU - Chen, Yu Shuin

AU - Chen, Yeh Long

AU - Lin, Ming-Fong

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The standard-of-care treatment for metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). Nevertheless, most tumors eventually relapse and develop into lethal castration-resistant prostate cancer (CRPC). Docetaxel is a FDA-approved agent for the treatment of CRPC; however, the tumor often quickly develops resistance to this drug. Thus, there is an immediate need for novel therapies to treat docetaxel-resistant PCa. In this study, we modified the structure of CIL-102 and investigated the efficacy of the derivatives against CRPC and docetaxel-resistant PCa. These novel CIL-102 derivatives inhibit CRPC tumorigenicity, including proliferation, migration and colony formation, and importantly, selectively inhibit CRPC cell proliferation over non-cancerous prostate epithelia. Computational modeling indicated the derivatives bind to β-tubulin and immunocytochemistry revealed the depolymerization of microtubules upon treatment. Western blot analyses reveal that pro-apoptotic and anti-oxidant pathways are activated, and MitoSOX and DCF-DA analyses confirmed increased reactive oxygen species (ROS) production upon treatments. Furthermore, CIL-102 derivatives effectively reduce the proliferation of docetaxel-resistant CR PCa cell lines. Our data indicate the potential of these compounds as promising therapeutic agents for CRPC as well as docetaxel-resistant CRPC.

AB - The standard-of-care treatment for metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). Nevertheless, most tumors eventually relapse and develop into lethal castration-resistant prostate cancer (CRPC). Docetaxel is a FDA-approved agent for the treatment of CRPC; however, the tumor often quickly develops resistance to this drug. Thus, there is an immediate need for novel therapies to treat docetaxel-resistant PCa. In this study, we modified the structure of CIL-102 and investigated the efficacy of the derivatives against CRPC and docetaxel-resistant PCa. These novel CIL-102 derivatives inhibit CRPC tumorigenicity, including proliferation, migration and colony formation, and importantly, selectively inhibit CRPC cell proliferation over non-cancerous prostate epithelia. Computational modeling indicated the derivatives bind to β-tubulin and immunocytochemistry revealed the depolymerization of microtubules upon treatment. Western blot analyses reveal that pro-apoptotic and anti-oxidant pathways are activated, and MitoSOX and DCF-DA analyses confirmed increased reactive oxygen species (ROS) production upon treatments. Furthermore, CIL-102 derivatives effectively reduce the proliferation of docetaxel-resistant CR PCa cell lines. Our data indicate the potential of these compounds as promising therapeutic agents for CRPC as well as docetaxel-resistant CRPC.

KW - Anti-microtubule agents

KW - CIL-102 derivatives

KW - CR PCa

KW - Docetaxel-resistant cancer

KW - Selectivity

UR - http://www.scopus.com/inward/record.url?scp=85052288765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052288765&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2018.07.039

DO - 10.1016/j.canlet.2018.07.039

M3 - Article

C2 - 30077739

AN - SCOPUS:85052288765

VL - 436

SP - 96

EP - 108

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -